Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 2009. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding their interests in the company's Ordinary shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details under the ShareReward Plan.
Material Changes
On October 8, 2009, several directors and officers acquired Ordinary shares through the Dividend Reinvestment element of the ShareReward Plan at a price of £12.34 per share. The specific acquisitions were:
- Mr A P Witty: 23 shares
- Mr J S Heslop: 23 shares
- Mr S M Bicknell: 23 shares
- Mr E J Gray: 23 shares
- Mr S A Hussain: 7 shares
- Mr D Learmouth: 23 shares
- Dr D Pulman: 9 shares
- Mr D S Redfern: 23 shares
- Ms C Thomas: 23 shares
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the share price of £12.34 against market data for October 8, 2009.
- Confirm the total number of shares acquired by each listed individual matches the company's internal records.
- Review the terms of the ShareReward Plan to understand the mechanics of the Dividend Reinvestment element.